Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans
Maria L. Maccecchini(St. Anna Hospital), Nigel H. Greig(National Institutes of Health), Mee Young Chang(QR Pharma (United States)), Varghese John(University of California, Los Angeles), Henrik Zetterberg(University of Wisconsin–Madison), Catherine Pan(Mercer Island School District)
Cited by 90
Related Papers
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease
|Nature Neuroscience|2019|1.7k
Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain
|Journal of Neurochemistry|2001|879